People channel feed – Endpoints News

People channel feed

Scientist-CEO accused of improperly using confidential info from unicorn Alector

6 years ago

AveXis scientific founder was axed — and Novartis names a new CSO in wake of an ethics scandal

6 years ago

Powerful Republican Chuck Grassley attacks Novartis CEO Narasimhan for ‘reprehensible’ decision to hide data

6 years ago

Trump's key drug pricing advisor O'Brien makes HHS exit

6 years ago

Make that 2 new US Big Pharma chiefs today, as Novartis remakes top team

6 years ago

Shifting focus to oncology, GSK recruits a cancer vet as new chief of US pharmaceuticals — adding another woman to the top ranks of biopharma

6 years ago

Key Apple digital health researcher set to join the Gates Foundation — report

6 years ago

Retrophin paid Martin Shkreli 'undisclosed sum' to settle yearslong legal disputes

6 years ago

Melinta chief John Johnson jumps ship — with the chairman — from another troubled antibiotics play

6 years ago

Gilead's newly departed R&D chief re-emerges as CEO of a rival hep B biotech looking to make a comeback

6 years ago

Loxo chief Josh Bilenker steps in (temporarily) to head oncology R&D at Eli Lilly as Levi Garraway steps out

6 years ago

Teva to lose CFO, with turnaround still under construction

6 years ago

Part procedure, part drug: Robert Ang joins Siddhartha Mukherjee in pioneering a new type of cell engineering

6 years ago

Joining Chang and Belldegrun, Rafael Amado takes a leading R&D post in the next big cell therapy revolution

6 years ago

Backed by Novo and OrbiMed, Thierry Abribat hauls in $75M for biotech #3 — a transatlantic upstart focused on rare diseases

6 years ago

Jumping into growing queue of buyers, Vertex chief targets a slate of new and 'larger' deals ahead

6 years ago

PD-L1, CD47 and now CD24? Star Stanford I/O scientist Irv Weissman points to a ‘major’ new cancer target

6 years ago

Adaptimmune R&D chief Amado hits the exit amid a top-level shakeup as new CEO tries to revive ebbing enthusiasm

6 years ago

FDA chief backs 2 new pathways to spur drug importation — but analysts shrug it all off

6 years ago

Gilead chief Daniel O’Day isn’t done making headlines — with more R&D deals and lots of new hires to come

6 years ago

Verastem taps board director and Eli Lilly vet Brian Stuglik to right the commercial boat

6 years ago

Strapped for cash, Woodford's unraveling continues as listed fund considers kicking him out as manager

6 years ago

Wellcome Trust joins warning for no-deal Brexit, calls on Boris Johnson to cast R&D vision

6 years ago

Vertex rushes to assure Wall Street that Jeff Leiden is keeping a hand on the reins as one analyst questions succession plans

6 years ago

First page Previous page 75 76 777879 80 81 Next page Last page